German Company Begins Testing Possible Vaccine on Humans

BERLIN (AP) —
The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany. (Reuters/Ralph Orlowski/File Photo)

German pharmaceutical company BioNTech says it has begun testing a potential vaccine for the new coronavirus on volunteers.

BioNTech, which is working with U.S.-based Pfizer, said Wednesday that 12 participants of a clinical trial in Germany have received doses of the vaccine candidate BNT162 since April 23.

Numerous pharmaceutical companies are racing to deliver a vaccine for the virus that has caused a pandemic and led to more than 215,000 deaths worldwide and sickened at least three million people.

BioNTech said in a statement that in a next step, it will begin increasing the dose of BNT162 in a trial involving about 200 participants aged 18 to 55.

The company said it expects to receive regulatory approval to begin trials in the United States soon.

To Read The Full Story

Are you already a subscriber?
Click to log in!

Hamodia Logo